Royalty-Free Innovations are available for free, with no up-front or trailing royalties, and a basic short-form agreement.
If you are interested in actively progressing a Royalty-Free Innovation, let us know about your organisation and your plans, including:
- The business, consumer, environmental and/or social need that you plan to focus on, and how you plan to use the Royalty-Free Innovation to meet this need;
- Any further development and protection of the Royalty-Free Innovation that you plan to undertake, including any ongoing engagement with QUT and any ongoing IP protection;
- Key technical and commercial milestones that you plan to achieve over the next 1-3 years, and the total resources that you plan to dedicate to the progression of the Royalty-Free Innovation;
- Any existing products, processes or services that you have progressed to date, and any synergies between them and the Royalty-Free Innovation; and
- Your managerial capability and general reputation in the market.
Please contact us for general information or if you would like to be considered for a specific Royalty-Free Innovation.
Chlamydial TFI Diagnostic
QUT researchers have developed an ELISA serology screening method which may rapidly identify women with Tubal Factor Infertility (TFI) caused by past repeated, chronic and untreated Chlamydia trachomatis infection.
QUT researchers have developed a peptide-based ELISA serology screening method which may rapidly identify women with Tubal Factor Infertility (TFI) caused by past Chlamydia trachomatis infection. The assay detects antibodies against the bacteria C. trachomatis that may be present in the serum of patients after chronic infection.
Chlamydia trachomatis is the most common reportable disease in the USA, with 70-80% of cases believed to be asymptomatic. Fallopian tube damage caused by chronic C. trachomatis infection can be difficult to detect and can often lead to misdiagnosis followed by unsuccessful intrauterine insemination and/or ovulation induction cycles, which can take at least 6 - 12 months to complete. The developed diagnostic has application for infertility testing in a clinical testing environment.
- Primary Care (GP)
- Sexual health
- Family Planning
- Infertility Management
- IVF Clinic
QUT researchers have worked closely with Australian IVF clinicians whilst developing and validating this diagnostic. qutbluebox seeks a partner interested in taking a non-exclusive, royalty-free license to bring the chlamydia diagnostic technology to market.
Dr Tim Evans
Contact Phone Number:
+61 7 3138 9426